Molecular Classification of Persistent Fever Syndromes

Abstract

Persistent fever syndromes constitute a diagnostic and therapeutic challenge due to their heterogeneous etiologies and overlapping clinical manifestations. Advances in molecular medicine have enabled the dissection of these syndromes based on genetic, immunologic, and cellular profiles, allowing for more precise classifications and targeted interventions. This review synthesizes current evidence regarding the molecular underpinnings of persistent fever syndromes, highlighting their epidemiology, pathogenesis, risk factors, clinical presentation, diagnostic approaches, and management strategies. The review also explores recent molecular discoveries, guideline-based recommendations, and the implications for clinical practice.

Introduction

Fever of prolonged duration—commonly defined as fever persisting beyond three weeks despite thorough initial evaluation—poses significant diagnostic complexity for clinicians. Traditionally, persistent fever syndromes have been categorized based on clinical and pathological findings; however, the advent of molecular technologies has ushered in an era of classification grounded in genetic and immunologic mechanisms. Such an approach not only improves diagnostic accuracy but also aids in the development of targeted therapies, underscoring the clinical importance of molecular classification in persistent fever syndromes.

Epidemiology / Disease Burden

The global burden of persistent fever syndromes is significant, particularly in pediatric populations and in regions with high prevalence of infectious and autoinflammatory conditions. Population-based studies demonstrate that up to 5% of fevers referred to tertiary care remain unexplained after initial workup. The prevalence of monogenic autoinflammatory syndromes, such as Familial Mediterranean Fever (FMF) and Tumor Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS), varies with ethnicity and geographical location. Additionally, persistent fever remains a frequent manifestation in systemic autoimmune diseases and certain malignancies, highlighting the necessity for a nuanced, molecularly informed diagnostic approach.

Pathophysiology

The pathophysiology of persistent fever syndromes is diverse, encompassing infectious, inflammatory, neoplastic, and genetic etiologies. Molecular classification distinguishes between autoinflammatory syndromes—driven by innate immune system dysregulation and typically associated with mutations in genes encoding inflammasome components (e.g., MEFV, NLRP3)—and autoimmune fevers, which involve adaptive immunity and autoantibody production. Infectious causes may be elucidated through pathogen-specific nucleic acid detection. Malignancy-associated fevers often relate to cytokine release by tumor cells. The identification of molecular drivers has deepened understanding of these syndromes and enabled the categorization of patients based on mechanistic pathways rather than just clinical features.

Risk Factors

Genetic predisposition is a key risk factor for many persistent fever syndromes, with mutations in genes such as MEFV, TNFRSF1A, and NLRP3 conferring high susceptibility to autoinflammatory conditions. Family history, consanguinity, and specific ethnic backgrounds amplify risk in hereditary syndromes. Environmental factors, such as infectious exposures and immune-modulating medications, can precipitate or unmask underlying molecular defects. Immunodeficiencies—either primary or secondary—also increase vulnerability to persistent fevers, particularly through impaired pathogen clearance or dysregulated immune responses.

Clinical Features

Patients typically present with recurrent or persistent fever, often accompanied by systemic symptoms such as rash, arthralgia, lymphadenopathy, hepatosplenomegaly, and serositis. The clinical phenotype varies by molecular subtype; for instance, FMF is characterized by short, self-limited febrile episodes with serositis, while TRAPS manifests as prolonged, migratory erythematous rashes and myalgia. Other features, such as mucocutaneous ulcers or sensorineural hearing loss, may point toward specific syndromic diagnoses. Recognition of associated organ involvement and response to empirical therapies provides additional diagnostic clues.

Diagnosis

Diagnostic evaluation of persistent fever syndromes requires a combination of clinical acumen and advanced laboratory testing. Initial workup includes thorough history, physical examination, and screening for common infectious, rheumatologic, and neoplastic causes. Molecular diagnostics—such as targeted gene panels, whole exome sequencing, and next-generation sequencing—enable identification of pathogenic mutations in suspected autoinflammatory syndromes. Biomarkers like serum amyloid A, C-reactive protein, and cytokine profiles assist in disease activity assessment. In certain cases, functional immunologic assays or tissue biopsy may be necessary to clarify disease mechanism.

Treatment & Management

Management strategies are guided by underlying molecular mechanisms. For monogenic autoinflammatory syndromes, colchicine remains the cornerstone for FMF, while interleukin-1 inhibitors (anakinra, canakinumab) are effective in NLRP3-associated periodic fever syndromes. Tumor necrosis factor inhibitors are indicated for TRAPS and Behçet's disease. Infectious etiologies are managed with targeted antimicrobial therapy, whereas autoimmune fevers may require immunosuppression (glucocorticoids, disease-modifying anti-rheumatic drugs). Supportive care and monitoring for complications, such as amyloidosis or secondary infections, are essential components of long-term management.

Recent Advances / Emerging Therapies

Recent years have witnessed substantial progress in the molecular dissection of persistent fever syndromes. Whole genome and transcriptome analyses have uncovered novel gene mutations and regulatory pathways implicated in fever pathogenesis. Advanced biologics targeting specific cytokines (IL-1, IL-6, TNF-α, interferon pathways) have demonstrated efficacy in refractory cases. Ongoing clinical trials are evaluating JAK inhibitors and anti-IL-18 therapies as potential options. Furthermore, precision medicine approaches—combining genotypic, transcriptomic, and proteomic data—are being integrated into diagnostic algorithms, facilitating individualized patient care.

Guideline Recommendations

Contemporary guidelines from the European League Against Rheumatism (EULAR), American College of Rheumatology (ACR), and International Society of Autoinflammatory Diseases (ISAD) emphasize the incorporation of molecular testing in the diagnostic workflow for persistent fever syndromes. Early genetic evaluation is recommended for children and young adults with recurrent unexplained fevers and a suggestive family history. Treatment guidelines advocate for mechanism-based therapy, with escalation to biologics in cases unresponsive to first-line agents. Regular monitoring for disease activity, organ involvement, and treatment-related adverse effects is essential for optimal outcomes.

Conclusion

Molecular classification has revolutionized the approach to persistent fever syndromes, enabling precise diagnosis and the application of targeted therapies. Integration of molecular diagnostics into routine clinical practice enhances patient stratification, informs prognosis, and underpins evidence-based management. Ongoing research into the molecular landscape of these syndromes promises to further refine classification systems and therapeutic options, ultimately improving outcomes for patients with these complex conditions.